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Theiler's viruses have been known for many years to cause an encephalomyelitis
inmice (1, 2), and have been classified in the picornavirus family (3) . The DA strain
of Theiler's murine encephalomyelitis viruses (TMEV)' can cause a biphasic cen-
tral nervous system (CNS) disease in mice (4) : acute polioencephalomyelitis and/or
chronic inflammatory demyelinating disease, depending on the dose and strain of
the virus and genetic background of the mouse . The former is clearly the result of
direct viral cytopathic effects, while the pathogenesis of the latter is under intense
exploration .
The CNS disease induced byTMEV is an animalmodel for human demyelinating
diseases, including post-infectious encephalomyelitis and multiple sclerosis (4-6) .
Both direct viral (7-10) and immune-mediated (11-13) mechanisms affecting oligoden-
drocytes and/or myelin have been proposed to initiate inflammatory events within
the CNS, leading to the chronic demyelination . Immune-mediated mechanisms in-
clude an : "innocent bystander" theory ; immunologic injury to oligodendrocytes in-
fected with virus; and virus-induced autoimmune events (5, 6, 14, 15) . Autoimmune
eventsmay be induced by sensitization to myelin antigens that are secondarily released
by viral infection of oligodendrocytes, or induced by the presence of acommon epi-
tope between virus and myelin components resulting in crossreactiveimmune response .
We have proposed amechanism in which viruses may initiate orenhance autoim-
mune diseases by possessingcommon or crossreacting determinants (molecularmim-
icry) with selfcomponents (16) . In earlier studies, we found that mAbs to viral pro-
This work was supported by the National Institutes of Health (NS-23162) and the National Multiple
Sclerosis Society (GR1780) .
Address correspondence to Robert S. Fujinami, Department of Pathology-M-012, School of Medi-
cine, University of California, San Diego, CA 92093 .
r Abbreviations used in this paper: ABC, avidin-biotin-peroxidase complex ; BBB, blood brain barrier ;
BHK, baby hamster kidney ; CNS, central nervous system ; EAE, experimental allergic encephalomye-
litis; GC, galactocerebroside ; HRPO, horseradish peroxidase; MBP, myelin basic protein ; PFU, plaque-
forming unit; RT, room temperature ; TMEV Theiler's murine encephalomyelitis virus.
J . Exp . MED . C The Rockefeller University Press - 0022-1007/90/06/1893/15 $2.00
￿
1893
Volume 171 June 1990 1893-19071894
￿
IMMUNE DEMYELINATION IN THEILER'S VIRUS INFECTION
teins could react with host cell components for measles, herpes, and vaccina viruses,
i.e., both RNA and DNA viruses (17, 18). These studies demonstrated the existence
of common determinants between viruses and cellular- or tissue-specific elements.
In addition, we were able to induce an experimental allergic encephalomyelitis (EAE)-
like disease by sensitization ofanimals with a viral peptide havinga sequence similarity
with the encephalolitogenic (disease-inducing) region of myelin basic protein (MBP)
(19). Sensitized animals generated autoantibody that reacted with the host protein,
MBP, and PBMC proliferated when cultured in the presence ofviral peptide or with
MBP This previous study demonstrated that a virus (viral peptide) that shares a
common determinant with a disease-inducing epitope could initiate autoimmune
disease.
A similar crossreactive immune response is a possible contributing factor for virus-
induced demyelinating diseases of humans. For example, in patients with post-
infectious encephalomyelitis after measles virus infection, response of lymphocytes
to MBP and lack of evidence of viral invasion of the CNS have been demonstrated
(20), suggesting an autoimmune pathogenesis of demyelination. The existence of
common immunologic element(s) between virus and MBP or other CNS compo-
nents is a possible event, although this remains to be determined.
In another report, we have described mAbs to TMEV (DA strain), and discov-
ered that one of these mAbs, H8, reacted both with TMEV viral protein VP-1 and
lipid-like moieties, including galactocerebroside (GC) (21). This indicated an over-
lapping epitope between TMEV VP-1 and GC-like molecules. GC is a major lipid
component ofmyelin (22). Others have demonstrated that immunization ofanimals
with GC or passive transfer of anti-GC antibody to animals could lead to demye-
linating disease (23-26). If mAb H8-like antibodies are produced in mice after TMEV
infection, they couldplay an active role in demyelination through an immune-mediated
process.
Here, we describe the binding of mAb H8 to oligodendrocytes in brain cell cul-
tures and to myelin structures in CNS tissue sections. We further document an in
vivo demyelinating effect ofmAb H8 and the presence of antibody(s) with the same
specificity as mAb H8 in the sera of mice chronically infected with TMEV Our
results indicate that antibody(s) with such specificities are generated after infection,
can enhance demyelination, and contribute to the observed pathology. This is the
first report demonstrating that an antibody to virus can augment demyelination of
CNS in vivo.
Materials and Methods
Production of mAbs to TMEV and Characterization of mAb H8
The details for production and characterization ofmAbs to TMEVwere previously reported
(21). Briefly, BALB/c mice were inoculated intracerebrally with 5 x 105 plaque-forming units
(PFU) of a tissue culture-derived virus, DA strain of TMEV. The DA strain of TMEV was
originally obtained from J. Lehrich and B. Arnason (27). After 6 wk, mice were boosted
intraperitoneally with 10' PFU of virus on days -3, -2, and -1 before fusion. Spleens were
removed and cells fused with myeloma cells. After screening, hybridoma-cloned cell lines
producing mAbs that reacted with TMEV and/or with CNS antigens, including GC (Sigma
Chemical Co., St. Louis, MO) by ELISA (28), were obtained. One ofthese mAbs, H8, reacted
both with GC and TMEV in ELISA. In neutralization assays, mAb H8 effectively neutral-
ized TMEV in vitro. In immunoblotting, mAb H8 strongly reacted with VP-1, the most ex-
ternal capsid protein of TMEV (21).YAMADA ET AL.
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Immunofluorescent Staining ofCulturedMouseBrain Cells with mAb H8 andAntibody to MBP
MouseBrainCell Culture. Brains from newbornmice were asceptically removed andmechan-
ically dissociated as previously described (29). The cells were suspended at a concentration
of 1.5 x 106 cells/ml in RPMI medium 1640 with L-glutamine and 2.0 g/liter sodium bicar-
bonate (Cell Culture Facility, University of California, San Diego, CA) supplemented with
10% FCS (Flow Laboratories, Inc., McLean, VA) and 1% antibiotics (Fungi-Bart StockSo-
lution; penicillin G [10,000 U/ml], streptomycin sulfate [10,000 14g/ml], and fungizone [25
1~g/ml] in normal saline; Irvine Scientific, Santa Ana, CA). 10 ml of the cell suspension was
distributed into 100-mm petri dishes (Falcon tissue culture dish 100 x 20-mm style; Becton
Dickinson Labware, Lincoln Park, NJ) containing glass Coverslips. The cultures were kept
at 37 °C in 5% C02. After 4 d in culture, the medium was changed everyother day. Cover-
slips from 21-d-old brain cultures were used for immunofluorescent labeling studies.
Immunofuorescent Labeling.
￿
Coverslips were incubated with mAbI=I8 (ascites) (diluted with
theculturemedium at 1:100) for2hat 37'C. As negative controls, Coverslips were incubated
with only themedium or an irrelevant mousemAb(ascites). Then, Coverslips were fixed with
95% ethanol and 5% acetic acid for 4 min at -20°C, and washed with PBS three times
for 5 min each at room temperature (RT). The Coverslips were then incubated with FITC-
conjugated goat antibody to mouse IgG (dilution 1:40) (CooperBiomedical, Inc., Malvern,
PA) for30 min at 37°C. Aftera PBSwash, Coverslips were mounted in glycerol/PBS solution
(glycerol 9/PBS 1) and observed using a fluorescent microscope.
Double ImmunofluorescentLabeling .
￿
Cellspositive for mAbH8 were morphologicallysimilar
to oligodendrocytes. Therefore, antibody to MBPwas used as amarker of oligodendrocytes
(30) in double labeling studies. Coverslips were incubatedwith a mixtureofmAb H8 (ascitic
fluid) (dilution 1:100) and rabbit antibody to MBP (Dako Corp., Santa Barbara, CA) (dilu-
tion 1:100) for 2 h at 37 °C. The Coverslips were then fixedwith 95% ethanol and 5% acetic
acid, as described above. After washingwith PBS, Coverslips were incubated with a mixture
of FITC-conjugated goat antibody to mouseIgG (dilution 1 :40) and rhodamine-conjugated
goat antibody to rabbit IgG (dilution 1:40) (CooperBiomedical, Inc.) for 30 min at 37°C.
The Coverslips were washed with PBS, mounted in glycerol/PBS solution, and observed using
fluorescent microscopy.
Immunohistochemical Staining of Mouse Brain Sections with mAb H8
Brain tissues were obtained from SJL/J mice and immediately frozen in liquid nitrogen.
Cryostat sections were cut(8-Amsections) andairdried. Theimmunostaining was performed
usingtheavidin-biotin-peroxidase complex(ABC)method (31). Sections were firstincubated
with isotonic solution (culture medium) containing 5olo normal goat serum for 30 min at
RT, and then incubated with mAb H8 (ascitic fluid) (1 :1,000) for 2 h at 37'C. The sections
were fixed in 95% ethanol and 5°Jo acetic acid for 4 min at -20°C. After washing with PBS
three times for 5 min each, sections were incubatedwith 1:40biotinylated horse anti-mouse
IgG (Vector Laboratories, Inc., Burlingame, CA) for 30 min at RT. After a PBS wash, sec-
tions were incubated with ABC (Vectastain ABC kit; Vector Laboratories, Inc.) for 30 min
at RT. Sections were washed with PBSandincubatedwith 0.06% 3,3'-diaminobenzidine (Sigma
Chemical Co.) and 0.03% hydrogenperoxide in 10 mM Tris (pH 7.5) for 7 min at RT. After
a PBS wash, sections were counterstained with hernatoxylin for 30 s.
As a positive control for the reactions with mAb H8, paraffin sections of brains from the
nude mice infected with theDA strain ofTMEV containing many TMEVinfected cells(32)
were used. Deparaffinized sections were incubated with mAb H8 for2 h at 370C, with bio-
tinylated horseanti-mouse IgG, and with ABC, and reactedwith the diaminobenzidine so-
lution.
In blocking experiments, mAb H8 was preincubated with baby hamster kidney (BHK)
cells infected with DA strain of TMEV (108 cells) overnight at 40C. After centrifugation at
5,000 g for5 min, supernatant fluid was used as an antibody preabsorbed with the antigen.
mAb H8 preincubated with uninfected BHK cells was also used as a control.
Injection of mAb H8 to Mice with Acute EAE
The experimental design to investigate the effect of mAb H8 on CNSin vivo was derived1896
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from methods described by Schluesener et al. (33) and Linington et al. (34). This is briefly
described.
Induction ofAcute EAE.
￿
SJL/J female mice, 4-6 wk old, were obtained from The Jackson
Laboratory, Bar Harbor, ME, and EAE was induced as described (35). Mice were anesthe-
tized and injected with 100 lul of a mixture of 16 mg mouse spinal cord homogenate in 50 /Al
ofPBS and 50 lug ofMycobacterium tuberculosis (Difco Laboratories, Inc., Detroit, MI) in 50 lul
ofIFA (Difco Laboratories, Inc.). Then, 24 and 72 h later, 101° organisms of washed, killed
Bordetellaßertussis (Michigan Department ofPublic Health, Lansing, MI) were injected intra-
venously to each mouse.
Injection ofmAb H8.
￿
On days 7 and 11 afterinduction ofEAE, 11 mice were given intrave-
nous injections of mAb H8 (ascitic fluid) (IgG 30 lug/body weight).
Control Groußs.
￿
Three groups of mice were used as controls: (a) EAE with intravenous
injection ofnormal mouse Ig (sameconcentration as mAb H8) (11 mice); (b) EAE only without
injection of mAb H8 (five mice); and (c) intravenous injection of mAb H8 without EAE in-
duction (five -trice). Normal mouse Ig was obtained from serum of normal SJL mice and
had no reactivity with TMEV antigen, as determined by ELISA. The Ig fraction was ob-
tained by precipitation at 4°C with 50% saturated ammonium sulfate, and the precipitate
was dialyzed for 2 d against several changes of PBS. The Ig concentrations of the normal
mouse Ig fractions, as well as of mAb H8, were determined by ELISA using normal mouse
IgG (ICN Biomedicals, Lisle, IL) as a standard of known Ig concentration.
Clinical Observations.
￿
Clinical signs were evaluated by modification of the criteria by Pet-
tinelli et al. (36), graded on a 0-5 scalewith increasing severity: 0, no abnormality; 1, a flaccid
tail with or without mild hind leg weakness, or mildly unsteady gait without flaccid tail; 2,
flaccid tail and moderate hind limb weakness; 3, marked (but not complete) paralysis of the
hind limbs with or without mild forelimb weakness; 4, total paralysis ofthe hind limbs with
moderate forelimb weakness; 5, quadriplegia or a premorbid state.
Pathological Evaluations.
￿
On day 13 after induction of EAE, mice were perfused with 4%
paraformaldehyde in PBS. The brains were post-fixed in the same fixative, cut in the median
saggital direction, and embedded in paraffin. Paraffin sections ofthe brains, 5-lam thick, were
stained with hematoxylin and eosin, and with antibody to MBP for detection ofmyelin. Im-
munostaining with anti-MBP antibody was performed using the ABC method (31).
Deparaflïnized sections were incubated with rabbit antiserum to MBP (Dako Corp.) (diluted
1 :300) for 2 h at 37°C, followed by biotinylated goat anti-rabbit IgG and ABC, and reacted
with the diaminobenzidine/H202 solution.
The spinal cords were post-fixed in 2.5% glutaraldehyde in 0.1 M phosphate buffer. At
four different levels, including one cervical, two thoracic, and one lumbo-sacral portions,
each spinal cord was cut, osmicated, and embedded in resin. Approximately 1-lum thick sec-
tions were cut from resin-embedded tissues ofthe spinal cords at the four levels, and stained
with toluidine blue.
Quantification ofDemyelination and Inflammation.
￿
The degree ofdemyelination was quantified
usingtoluidine blue sections of the spinal cords, since this method is most suitable in light
microscopic observations of demyelination. In each mouse, sizes of both the demyelinated
area and area of white matter were measured in four sections of the four different levels of
the spinal cord by a computer-assisted morphometric system (C-2 Image Analyzer; Olympus
Corporation of America, New Hyde Park, NY). The proportion of the total demyelinated
area to total area of the white matter was then calculated for each mouse. Results of each
mouse were,expressed by 100 x (demyelinated area/area of white matter). For inflammation,
&_total number of perivascular infiltrates in the brain and spinal cord-sections were counted
for each mouse.
ELISA of mAb H8 and TMEVinfected and Normal Mouse Sera
Sera were obtained and pooled from normal SJL/J mice (age matched) and from 10 in-
fected SJL/J mice that were intracerebrally inoculated with TMEV (DA) (105 PFU) 4-8 wk
prior. These mice were 7-8 wk old at the time ofinoculation, and pathologically showed chronic
inflammatory demyelinating disease of the spinal cord white matter when the sera were ob-
tained 4-8 wk afterthe inoculation. Ig fractions were isolated by 50% saturated ammoniumYAMADA ET AL.
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sulfate from: (a) normal mouse sera; (b) TMEVinfected sera; and (c) mAb H8 (ascitic fluid).
Ig concentrations were determined by ELISA. Ig concentration was adjusted to 4 mg/ml
in all the three Ig fractions.
ELISAforAntibody to TMEV (DA).
￿
Antibody to TMEV (DA strain) was quantified by
ELISA as described by Rice and Fujinami (28). TMEV antigen preparation was made as
a cytoplasmic extract of infected cells and processed (37). Briefly, 96-well plates (Linbro/
Titertek; Flow Laboratories, Inc.) were coated with 100 /Al of TMEV (DA) antigen at 5 pg
protein/ml in PBS overnight. After blocking with 10% FCS in PBS, serial dilutions of Ig
fractions were applied and incubated for 90 min at RT. After washing, 100 141 ofhorseradish
peroxidase (HRPO)-labeled affinity-purified antibody (goat) to mouse Ig (Kirkegaad & Perry
Laboratories, Inc., Gaithersburg, MD) at a 1 :1,000 dilution was added, and plates were in-
cubated for 90 min at RT. After washing, 100 pl of the substrate solution consisting of 3 mM
H202 and 2 .2 mM O-phenylene diamine in 0.1 M sodium citrate buffer (pH 5.0) was added,
and plates were incubated for 30 min in the dark. The reaction was stopped by the addition
of 100 pl of 1 N HCl, and optical densities (OD492) were measured on a Titertek Multiskan
(Flow Laboratories, Inc.).
ELISAforAntibody to GC.
￿
Antibody to GC was quantified by ELISA as described by
Fujinami et al. (21). Briefly, GC was solubilized in chloroform/methanol (1 :1) at a concentra-
tion of 1 mg/ml. The solution was further diluted to 5 14g/ml, and 100 141 was then added
to 96-well plates (3912 Micro Test III Flexible Assay Plate; Falcon Labware, Oxnard, CA).
The chloroform/methanol was removed by evaporation, and the assay was performed as de-
scribed in ELISA for antibody to TMEV.
Competition ELISA.
￿
Antibody with similar specificity as mAb H8 in sera was analyzed
by competition ELISA(38). Briefly, mAb H8 was coupled to HRPO by the periodate method
(39). Competition assays were performed as follows. 96-well plates were coated with TMEV
(DA) or GC antigen as described above. Various dilutions of the unlabeled first (inhibiting)
antibodies (Ig fractions) from TMEV (DA)-infected sera, normal mouse sera, or mAb H8
were added to the wells and incubated for 90 min at RT. Then a standard amount of the
second antibody, mAb H8, labeled with HRPO, was added to the wells and incubated for
90 min at RT. The plates were then washed, and 100 fAl of the substrate solution was added.
The enzyme reaction was terminated after 30 min by the addition of 100 Al of 1 N HCl into
the wells. OD492 were read with a Titertek Multiskan (Flow Laboratories, Inc.). In this
system, if the unlabeled first (inhibiting) antibodies recognize the same (or nearby) epitope
on TMEVor GC as mAb H8, the bound first antibodies prevent the labeled second antibody
(HRPO-conjugated mAb H8) from binding. Blocking of the HRPO-conjugated antibody
by mAb H8 itself was defined to be 100% blocking or inhibition. Calculated was percent
blocking of HRPO-conjugated mAb H8 by Ig from DA-infected sera or normal sera at the
same Ig concentration as mAb H8.
Results
Immunostainings ofBrain Cell Cultures andBrain Tissue Sections.
￿
In mouse brain cell
cultures, small, round cellswith or without cellular processes were labeled with mAb
H8 (Fig. 1 a). These cells were growing on the top of the other large flat cells and
appeared morphologically similar to oligodendrocytes. To determine the nature of
the positive cells, double-labeling studies were performed. These small round cells
were double labeled with mAb H8 and anti-MBP (Fig. 1 a and b). These data indi-
cate that the mAb H8+ cells were myelin-producing cells, i.e., oligodendrocytes.
In immunohistochemical studies of frozen mouse brain sections, myelin struc-
tures in the brain were positively stained with mAb H8 (Fig. 2 a). This reaction
was inhibited by preincubation ofmAb HS with the TMEVinfected BHK cells (Fig.
2 b), but not with uninfected BHK cells. As a positive control, mAb H8 stained
TMEVinfected cells in TMEVinfected brain (Fig. 3 a). This staining of TMEV1898
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FIGURE 1 .
￿
21-d-old brain cell culture from newborn mice . Double immunofluorescent labeling
with mAb H8 (demonstrated by FITC [a]) and antibody to MBP (by rhodamine [b]) . Small
round cells with or without thin cellular processes are labeled with mAb H8 (a) . These cells are
lying over flat large cells in culture . The cells positive for mAb H8 (a) are double labeled with
antibody to MBP (b) (x230) .
FIGURE 2 .
￿
Frozen section of mouse brain . mAb H8 immunostains myelin structures in stria-
tumofthe brain (a) . The positive immunoreaction is blocked by preincubation ofmAbH8 with
TMEV (DA) antigen (b) (x 124).YAMADA ET AL .
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FIGURE 3 .
￿
TMEVinfected brain . mAb H8 immunostains infected cells (a), and the reaction
is blocked by preincubation of mAb H8 with TMEV (DA) antigen (b) (x250) .
antigen was also blocked by preincubation of themAb with TMEV antigen (Fig.
3 b) . mAbH8 did not stain myelin structures in paraffin-embedded tissue sections,
indicating that the antigen was labile or solubilized by the embedding and/or
deparaffinizing procedures .
Modulation ofEAEby mAbH8.
￿
To investigate the effect ofmAbH8under patho-
logic conditions, mAbH8 was passively transferred into mice afterEAE induction .
No clinical diseasewas observed in mice treated with mAbHS alone (Table I) . Mice
givenCNS antigen with or without mAbH8 developed clinical signs ofEAE. The
clinical signs in EAE mice givenmAbH8 tended to be more severe than thoseEAE
mice treated with normal mouse Ig or EAE mice without treatment . However, the
clinical severity varied from mousetomouse. Statistical analysis showed no significant
difference in clinical score among the three groups (Table I) .
Histopathologically, in EAE mice with or without antibody treatment, an acute
meningoencephalomyelitis was observed . No lesionswere observed in mice injected
with mAb H8 alone. Lesions in EAE mice were characterized by meningeal and
perivascular infiltrates of inflammatory cells consisting of lymphocytes and poly-
morphonuclear cells associated with rather mild demyelination. Most parenchymal
involvement was distributed within the spinal cord, brainstem, and cerebellar white
matter. Thedistribution ofinflammatory lesions were similar amongthethree groups
with EAE. Although the number ofperivascular infiltrates appeared to be increased1900
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TABLE I
Modulation of Acute EAE by Intravenous Injection of mAb H8
Data are mean t SD.
' Clinical signs graded by a 0-5 scale with increasing severity. See text for details.
I The total number of perivascular infiltrates in the brain and spinal cords.
s Demyelinated area/white matter area. Areas are total of four levels of the spinal cord.
II Value of demyelinated area in EAE with mAb H8 is significantly higher than that in EAE
with normal mouse Ig (p < 0.001) and than that in EAE only (p < 0.001) by student's t test.
There is no significant difference in the clinical scores or in the numbers of perivascular
infiltrate.
in EAE mice receiving mAb H8 vs. EAE mice with normal mouse Ig or without,
statistical analysis demonstrated no significant difference among the three groups
with EAE (Table I). In contrast, the demyelination in EAE mice treated with mAb
H8 was more extensive than that observed in EAE mice injected with normal mouse
Ig or without treatment (Figs. 4 and 5, Table I).
Quantification of demyelination was performed by examining cross sections of
resin-embedded spinal cord stained with toluidine blue. These materials were more
suitable for fine and morphometric evaluation of demyelination rather than paraffin-
embedded brain sections immunostained with anti-MBP In EAE mice injected with
normal mouse Ig or without treatment (Fig. 4), loss ofmyelin was commonly found
in and frequently confined to subpial areas of nerve root entry zones of the spinal
cord accompanied by infiltration of inflammatory cells. In EAE mice treated with
mAb H8 (Fig. 5), the demyelination was widely distributed in subpial areas and
often in the deep white matter, as well as lesions around root entry zones. Those
lesions were frequently, but not always, associated with inflammation. Quantitative
analysis of demyelination clearly demonstrated a significant increase of demyelina-
tion in EAE mice receiving mAb H8 (10-fold) compared with EAE mice treated
with normal mouse Ig or without (p < 0.001) (Table I).
Analysis of TMEVinfected Sera by ELISA.
￿
To determine whether antibodies like
mAb H8, which has specificity to GC and TMEV and plays a role in demyelination,
were present in mice with chronic infection ofTMEV (DA), the sera were analyzed
by quantitative ELISA. Ig concentrations were first determined from the various
sources. Ig concentrations were 2.8 mg/ml in normal sera, 10.0 mg/ml in TMEV
infected sera, and 4.8 mg/ml in mAb H8 ascitic fluid, as determined by ELISA.
The Ig fractions were obtained as described in Materials and Methods, and used
in the following assays after the Ig concentrations were adjusted to 4 mg/ml.
The results of the ELISAs are shown in Table II. The Ig fraction from normal
sera did not contain antibody to TMEV or GC. The Ig fraction from mAb H8 (as-
cites) had an antibody titer (loge) of 17.3 to TMEV and 9.2 to GC. Similarly, the
Treatment
No. of
mice
Clinical
score'
Perivascular
infiltratet
Demyelinated
areas
EAE + H8 11 3.98 t 1 .31 37.1 f 17 .3 5.08 t 1 .81 R
EAE + normal mouse Ig 11 2.64 t 1 .55 24.6 t 16.6 0.83 0.57
EAE only 5 2.60 t 1 .62 21.8 t 11 .1 0.55 t 0.24
HS only 5 0 0 0YAMADA ET AL .
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FIOuRE 4.
￿
Representative spinalcord
section ofEAE mice treated with nor-
mal mouse Ig. Resin-embedded section
stainedwith toluidine blue . A small de-
myelinated area with inflammatory
cells is found to be confined to an en-
try zone of the ventral root (arrow)
(x75) .
Ig preparation from the infected sera had a titer of 15 .1 toTMEV and 6.2 to GC .
To investigate thepresence ofantibody(s) with the same or similar specificity as mAb
H8 in sera, competitionELISAs were performed . Competition ofthe unlabeled first
antibody (Ig from the infected or normal sera) with the labeled second antibody
(HRPO-conjugated mAb H8) in binding to TMEV or GC antigen was analyzed
as described in Materials andMethods. By competitionELISA forTMEV antigen,
percent blocking ofHRPO-conjugated mAb H8 by Ig from the infected sera was
32%. Further, competition ELISA forGC antigen revealed 31% blocking ofHRPO-
conjugated mAb H8 by Ig from the infected sera. No inhibition of binding of the
HRPO-conjugated mAb H8 to TMEV or GC antigen could be demonstrated in
the Ig fraction from normal serum .
Discussion
This is the first report demonstratingthat an antibody to viruscan enhance demy-
elination of CNS in vivo. Our results indicate that antibodies, as those generated by
immune response to TMEV, can reactwith myelin and oligodendrocytes, andcon-
tribute to demyelination through an immune process.1902
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FIGURE 5 .
￿
Representative spinal cord section ofEAEmice treatedwithmAbH8. Resin-embedded
section stained with toluidine blue . Demyelinated areas are found in deep white matter of the
lateral funiculus (arrow heads), as well as in subpial area aroundthe ventral root entry zone (arrows)
(a) . Higher magnification of the lesion indicated by arrow head with asterisk in a is shown in
b . Spongiform changes and loss of myelin are observed (a, x82 ; b, x500) .
Ourresultsofimmunohistochemical studies have demonstrated that mAbH8 binds
to oligodendrocytes in mouse brain cell cultures and myelin structures in brain sec-
tions . Double-immunolabeling studies using brain cell cultures revealed that mAb
H8+ cells contained MBP as well, indicating that mAb H8 binds to myelin-
producing cells (oligodendrocytes) . Immunohistochemistry using frozen brain sec-
tions disclosed that mAbH8 reacted with myelin structures at a tissue level . A pos-
sible reasonwhymAbH8 did not stainmyelin structures in paraffin-embedded brain
sections canbe explained since lipid antigens such asGC, with whichmAbH8 reacts
as well as withTMEVVP-1 (21), are lost during processing forparaffin embedding
oftissuesand deparaffinization. Themolecularbackground of this crossreaction be-
tween TMEV VP-1 andGC is under study. It is possible that there is mimicry in
molecular conformation between VP-1 ofTMEV and lipid-like structures such as
GC, or that the presence of overlapping determinants may be found (21) .
The experimental modulation ofEAE by mAbH8 demonstrated that this anti-
body can augment demyelination in vivo in mice . Sincemice treated with mAbH8
alone didnotdisplay demyelination, destruction or alteration ofthe blood-brain barrier
(BBB) by EAE induction, i.e ., inflammation, appears to be an important event for
mAb H8, which is systemically administered to enter the CNS. This is consistentYAMADA ET AL .
TABLE II
ELISA of Sera from TMEV-infected and Normal Mice and of mAb H8
for Antibodies to TMEV and GC andfor Antibody
with Same Specificity as mAb H8
Titers (loge) in ELISA .
t Percent blocking of HRPO-conjugatedmAb H8 . Blocking by mAbH8 itself
is defined to be 100% . See text for the details of competition ELISA .
S Ig fractions were prepared at the same concentration (4 mg/ml) and used for
ELISA .
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with reportswhere passive transfer of anti-GC antibody could cause demyelination
inCNS when injected intraocularly (25, 26) or injected directly into peripheral nerves
(24) . Our results indicate that mAb H8, which has both antiTMEV and anti-GC
activities, can induce demyelination in vivowhen systemically transferred into mice
with EAE. Demyelination induced by the mAb may occur through complement-
or cell-mediated processes . Brosnan et al . (25, 40) have postulated that effector cells
provided by inflammation are necessary for anti-CNS antibodies to producedemye-
lination . In our experiments, demyelinated areas in mice with EAE givenmAb H8
were frequently associated with infiltration of mononuclear cells . It is possible that
mAbH8 can effectively produce demyelination in thepresence ofinflammatory cells
through an antibody-dependent cell-mediated process . Such studies detailing these
events have been initiated .
ELISA of sera from mice with chronic TMEV infection has shown that the sera
contained antibody(s) toGC as well as toTMEV, and that in competition ELISAs
forTMEV or GC antigen with HRPO-labeledmAb H8, a substantial part of the
Ig in the infected sera reacted with the same (or nearby) epitope as recognized by
mAbH8 . It is possible that damage to myelin by cytopathic effects ofTMEV infec-
tionmay result in thegeneration of antibody to GC . This cannot be entirely ruled out .
Ourdata indicate that such an antibody(s) in the sera could playarole in demyeli-
nation through an immune-mediated process. Barbano and Dal Canto (41) have
reported that serum and cells from TMEVinfected mice failed to injure myelinat-
ing cultures or to produce in vivo demyelination . In their in vivo passive transfer
experiment, mice were injected with splenocytes that were removed from TMEV
infected miceand incubated withMBP or with spinal cord homogenate, and at 10 d
after injection, the mice had no apparent disease in the spinal cords . This experimental
system is markedly different from ours, where an antibody to TMEV was injected
to mice with EAE. In our experimental model, the recipient micehadCNS inflam-
mation with alterations ofBBB due to acute EAE and received specific antibodies .
In other studies, Rodriguez et al . (42) reported that serum orCSF IgG fromTMEV
Anti-TMEV' Anti-GC"
Competition
HPRO-conjugated
mAb H8
TMEVt
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for :
GCI
0 /0 0 /0
Normal serrS 0 0 0 0
TMEV-infected seraS 15 .1 6 .2 32 31
mAb H8S 17.3 9 .2 100 1001
9
0
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infected mice did not bind to myelin or otherCNS components . In contrast, Cash
et al . (43) has described that Ig secreted by the B cells present in the inflammatory
CNS lesions ofTMEVinfected animals reacted with nonviral white manner com-
ponentsas well as with the viral capsid proteins, and they suggested that these auto-
reactive antibodies could have a role in demyelination . In their studies, such non-
viral whitematter components were present only in infected animals, andare somewhat
different from ours . Our data support thepresence for autoantibodies and their role
in demyelination .
Ourresults corroborate anautoimmune contribution in the demyelinating aspect
ofTMEV infection . In TMEV infection, an immune response to TMEV can lead
to generation ofantibodies to viral components, including VP-1, and myelin compo-
nents . VP-1 ofTMEV contains a highly exposed neutralizing epitope (44) . Such
an antibody in the sera can work as a neutralizing antibody against the viruses and
have an important role to eliminate virus from the animal . We have demonstrated
that another neutralizing antibody toTMEV (H7), which reacts with VP-1 but not
with GC, can play a dramatic role in the clearance of virus and survival of athymic
mice (45) . In contrast, antibody(s) ofH8 type could in turn contribute to CNS dis-
ease. This may occur when the BBB is broken afterTMEV infection of theCNS
and/or when the antibody is produced intrathecally by infiltrating cells . A part of
infiltrating inflammatory cells associated with the viral infection could play an effector
role for an antibody-mediated demyelination . Further studies clarifying the role of
the antibody-mediated demyelination areongoing usingmAbH8 in TMEVinfected
mice, as well as immune sera in EAE mice.
Summary
Theiler's murine encephalomyelitis virus (TMEV) causes a chronicdemyelinating
disease in mice . The mechanisms underlying the demyelination have not been fully
elucidated . We have raised amAb toTMEV (DA strain), H8, that reacts both with
TMEV VP-1 and galactocerebroside (GC). In mouse brain cultures, cells positive
for themAbH8 epitope were double labeled with antibody to myelin basic protein,
indicating that those cells were oligodendrocytes . Further, mAbH8 could immuno-
stain myelin structures in frozen sections from mouse brains . When injected intra-
venously into mice with acute allergic encephalomyelitis, mAbH8 increased by 10-
fold the size of demyelinated areas within the spinal cords. This is the first report
demonstrating that an antibody to virus canenhancedemyelinationofacentral nervous
system disease . Ig fractions from the sera of mice with chronic TMEV infection
had antibody(s) to GC, as well as to TMEV, as determined by ELISA . Further-
more, a competition ELISA forTMEV orGC antigen revealed that sera from these
infected mice contained antibody(s)with the same specificity asmAbH8 . Our results
indicate that antibodies generated by immune response to TMEV can react with
myelin and oligodendrocytes, and contribute to demyelination through an immune
process .
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